<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The objective of the present study was to examine the role of the <z:chebi fb="0" ids="2719,48432">angiotensin II</z:chebi> type 1 receptor (AT(1)-R) in the <z:mp ids='MP_0002055'>diabetes</z:mp>-aggravated <z:mp ids='MP_0003674'>oxidative stress</z:mp> and brain injury observed in a rat model of combined <z:mp ids='MP_0002055'>diabetes</z:mp> and focal <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain><z:mp ids='MP_0002055'>Diabetes</z:mp> was induced by an injection of streptozotoxin (STZ; 55 mg/kg iv) at 8 wk of age </plain></SENT>
<SENT sid="2" pm="."><plain>Two weeks after the induction of <z:mp ids='MP_0002055'>diabetes</z:mp>, some animals received continuous subcutaneous infusion of the AT(1)-R <z:chebi fb="68" ids="48706">antagonist</z:chebi> <z:chebi fb="0" ids="3347">candesartan</z:chebi> (0.5 mg.kg(-1).day(-1)) for 14 days </plain></SENT>
<SENT sid="3" pm="."><plain>Focal <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo>, induced by middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp>/reperfusion (MCAO), was conducted at 4 wk after STZ injection </plain></SENT>
<SENT sid="4" pm="."><plain>Male Sprague-Dawley rats (n = 189) were divided into five groups: <z:mpath ids='MPATH_458'>normal</z:mpath> control, <z:mp ids='MP_0002055'>diabetes</z:mp>, MCAO, <z:mp ids='MP_0002055'>diabetes</z:mp> + MCAO, and <z:mp ids='MP_0002055'>diabetes</z:mp> + MCAO + <z:chebi fb="0" ids="3347">candesartan</z:chebi> </plain></SENT>
<SENT sid="5" pm="."><plain>The major observations were that 1) MCAO produced typical <z:e sem="disease" ids="C0007785" disease_type="Disease or Syndrome" abbrv="">cerebral infarction</z:e> and neurological deficits at 24 h that were accompanied by elevation of <z:chebi fb="0" ids="13392">NAD(P)H</z:chebi> oxidase gp91(phox) and p22(phox) <z:chebi fb="2" ids="33699">mRNAs</z:chebi>, and <z:chebi fb="23" ids="18059">lipid</z:chebi> <z:chebi fb="0" ids="35923">hydroperoxide</z:chebi> production in the ipsilateral hemisphere; 2) <z:mp ids='MP_0002055'>diabetes</z:mp> enhanced <z:chebi fb="0" ids="13392">NAD(P)H</z:chebi> oxidase gp91(phox) and p22(phox) <z:chebi fb="2" ids="33699">mRNA</z:chebi> expression, potentiated <z:chebi fb="23" ids="18059">lipid</z:chebi> peroxidation, aggravated neurological deficits, and enlarged <z:e sem="disease" ids="C0007785" disease_type="Disease or Syndrome" abbrv="">cerebral infarction</z:e>; and 3) <z:chebi fb="0" ids="3347">candesartan</z:chebi> reduced the expression of gp91(phox) and p22(phox), decreased <z:chebi fb="23" ids="18059">lipid</z:chebi> peroxidation, lessened <z:e sem="disease" ids="C0007785" disease_type="Disease or Syndrome" abbrv="">cerebral infarction</z:e>, and improved the neurological outcome </plain></SENT>
<SENT sid="6" pm="."><plain>We conclude that <z:mp ids='MP_0002055'>diabetes</z:mp> exaggerates the <z:mp ids='MP_0003674'>oxidative stress</z:mp>, <z:chebi fb="0" ids="13392">NAD(P)H</z:chebi> oxidase induction, and brain injury induced by focal <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> </plain></SENT>
<SENT sid="7" pm="."><plain>The <z:mp ids='MP_0002055'>diabetes</z:mp>-aggravated brain injury involves AT(1)-Rs </plain></SENT>
<SENT sid="8" pm="."><plain>We have shown for the first time that <z:chebi fb="0" ids="3347">candesartan</z:chebi> reduces brain injury in a combined model of <z:mp ids='MP_0002055'>diabetes</z:mp> and <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> </plain></SENT>
</text></document>